Additional information
| Active substance | Regorafenib |
|---|---|
| Chemical name | 4-(4-((4-(2-(Methylcarbamoyl)pyridin-4-yl)oxy)phenylamino)phthalazin-1-yl)-3-fluorobenzenesulfonamide |
| Side effects | Hand-foot skin reactions, diarrhea, fatigue, hypertension, rash, decreased appetite, and infection |
| Effects | Inhibits tumor growth and reduces tumor vascularization |
| Dosage (sports) | Not applicable as it is not used for sports enhancement |
| Dosage (medical) | Typically 160 mg taken orally once daily for the first 3 weeks of a 4-week cycle |
| Half-life | Approximately 28 hours |
| Main action | Targets and inhibits tumor angiogenesis, oncogenesis, and the tumor microenvironment |
| Substance class | Kinase inhibitor |
| Formula | C21H15ClF4N4O3 |
| Storage conditions | Store at room temperature away from moisture and heat |
| Trade name | Stivarga |
| Blood pressure | Can cause hypertension |
| Also known as | BAY 73-4506 |
| Strength | 40mg |
| Lab Test | Monitoring of liver function and blood counts is recommended |
| Hepatotoxicity | Yes, can cause elevated liver enzymes and hepatotoxicity |
| Water Retention | Minimal |
| Use in sports | None, as it is not an enhancing drug |
| Manufacturer | Natco Pharmaceuticals Ltd. |
| Packing | 28 tabs/bottle |
Reviews
There are no reviews yet.